Na+ channelopathies and epilepsy: Recent advances and new perspectives

Expert Review of Clinical Pharmacology

Volumn 3, Issue 3, 2010, Pages 371-384

  Marini, Carla ^a   Mantegazza, Massimo ^b,c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Antiepileptic drugs; Dravet syndrome; Epilepsy; Epileptic encephalopathies; Excitability; Familial hemiplegic migraine; Fever; Focal epilepsy; GEFS+; Na+ channel; Na+ current; Neuron; Seizure

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOBAZAM; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; POTASSIUM CHANNEL KCNQ2; POTASSIUM CHANNEL KCNQ3; SODIUM CHANNEL NAV1.1; SODIUM CHANNEL NAV1.2; SODIUM CHANNEL NAV1.3; SODIUM CHANNEL NAV1.6; SODIUM CHANNEL NAV1.7; STIRIPENTOL; TOPIRAMATE; VALPROIC ACID; VOLTAGE GATED SODIUM CHANNEL;

ALZHEIMER DISEASE; BENIGN FAMILIAL NEONATAL INFANTILE SEIZURE; CHANNEL GATING; EPILEPSY; EPILEPTOGENESIS; FAMILIAL HEMIPLEGIC MIGRAINE; FEBRILE CONVULSION; GENE MUTATION; GENERALIZED EPILEPSY WITH FEBRILE SEIZURE; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; HOMOZYGOSITY; HUMAN; INTRACTABLE CHILDHOOD EPILEPSY WITH GENERALIZED TONIC CLONIC SEIZURE; LINKAGE ANALYSIS; LOSS OF FUNCTION MUTATION; MEMBRANE CONDUCTANCE; MISSENSE MUTATION; NERVE EXCITABILITY; NONHUMAN; PHARMACOGENETICS; PHENOTYPIC VARIATION; PROGNOSIS; REVIEW; SEIZURE; SEVERE MYOCLONIC EPILEPSY IN INFANCY; SODIUM CHANNELOPATHY; SODIUM CURRENT; SPLICING DEFECT; TRANSGENICS;

EID: 77952562760     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.10.20     Document Type: Review

References (145)

1. Pugliatti M, Beghi E, Forsgren L, Ekman M, Sobocki P. Estimating the cost of epilepsy in Europe: a review with economic modeling. Epilepsia 48 (12), 2224-2233 (2007).
2. Sander J W. The epidemiology of epilepsy revisited. Curr. Opin. Neurol. 16 (2), 165-170 (2003).
3. Annegers JF. The epidemiology of epilepsy. In: The Treatment of Epilepsy: Principles and Practice. Wylie E (Ed.). Williams and Wilkins, MD, USA (1996).
4. Helbig I, Scheffer IE, Mulley JC, Berkovic SF. Navigating the channels and beyond: unravelling the genetics of the epilepsies. Lancet Neurol. 7 (3), 231-245 (2008).
5. McCormick DA, Contreras D. On the cellular and network bases of epileptic seizures. Annu. Rev. Physiol. 63, 815-846 (2001).
6. Matsumoto H, Marsan CA. Cortical cellular phenomena in experimental epilepsy: interictal manifestations. Exp. Neurol. 9, 286-304 (1964).
7. Steinlein OK, Mulley JC, Propping P et al. A missense mutation in the neuronal nicotinic acetylcholine receptor 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat. Genet. 11 (2), 201-203 (1995).
8. Avanzini G, Franceschetti S, Mantegazza M. Epileptogenic channelopathies: experimental models of human pathologies. Epilepsia 48 (Suppl. 2), 51-64 (2007).
9. Catterall WA, Dib-Hajj S, Meisler MH, Pietrobon D. Inherited neuronal ion channelopathies: new windows on complex neurological diseases. J. Neurosci. 28 (46), 11768-11777 (2008).
10. Hodgkin AL, Huxley AF. Currents carried by sodium and potassium ions through the membrane of the giant axon of Loligo. J. Physiol. 116 (4), 449-472 (1952).
11. Crill WE. Persistent sodium current in mammalian central neurons. Annu. Rev. Physiol. 58, 349-362 (1996).
12. Mantegazza M, Yu FH, Powell AJ, Clare JJ, Catterall WA, Scheuer T. Molecular determinants for modulation of persistent sodium current by G-protein subunits. J. Neurosci. 25 (13), 3341-3349 (2005).
13. + channels. Proc. Natl Acad. Sci. USA 105 (48), 18994-18999 (2008).
14. Raman IM, Sprunger LK, Meisler MH, Bean BP. Altered subthreshold sodium currents and disrupted firing patterns in Purkinje neurons of Scn8a mutant mice. Neuron 19 (4), 881-891 (1997).
15. Stafstrom CE. Persistent sodium current and its role in epilepsy. Epilepsy Curr. 7 (1), 15-22 (2007).
16. Mantegazza M, Franceschetti S, Avanzini G. Anemone toxin (ATX II) -induced increase in persistent sodium current: effects on the firing properties of rat neocortical pyramidal neurones. J. Physiol. 507 (Pt 1), 105-116 (1998).
17. + channels in hypoxia-induced neuronal injuries. Clin. Exp. Pharmacol. Physiol. 27 (8), 569-574 (2000).
18. V1.1 and functional analysis of three epileptogenic mutations engineered in the human clone. A milestone even if actual functional effects may be different in vivo (see [112]).
19. Stys PK. General mechanisms of axonal damage and its prevention. J. Neurol. Sci. 233 (1-2), 3-13 (2005).
20. Waxman SG. Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis - current status. Nat. Clin. Pract. Neurol. 4 (3), 159-169 (2008).
21. Catterall WA. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron 26 (1), 13-25 (2000).
22. + channel family with the official nomenclature of the International Union of Pharmacology.
23. Goldin AL. Mechanisms of sodium channel inactivation. Curr. Opin. Neurobiol. 13 (3), 284-290 (2003).
24. Abriel H, Kass RS. Regulation of the voltage-gated cardiac sodium channel Nav1.5 by interacting proteins. Trends Cardiovasc. Med. 15 (1), 35-40 (2005).
25. Mantegazza M, Yu FH, Catterall WA, Scheuer T. Role of the C-terminal domain in inactivation of brain and cardiac sodium channels. Proc. Natl Acad. Sci. USA 98 (26), 15348-15353 (2001).
26. Carr DB, Day M, Cantrell AR et al. Transmitter modulation of slow, activitydependent alterations in sodium channel availability endows neurons with a novel form of cellular plasticity. Neuron 39 (5), 793-806 (2003).
27. Berendt FJ, Park KS, Trimmer JS. Multisite phosphorylation of voltage-gated sodium channel α subunits from rat brain. J. Proteome Res. 9 (4), 1976-1984 (2010).
28. Brechet A, Fache MP, Brachet A et al. Protein kinase CK2 contributes to the organization of sodium channels in axonal membranes by regulating their interactions with ankyrin G. J. Cell Biol. 183 (6), 1101-1114 (2008).
29. v) 1.2 channels by Fyn tyrosine kinase. J. Neurosci. 27 (43), 11543-11551 (2007).
30. Isom LL. Sodium channel b subunits: anything but auxiliary. Neuroscientist 7 (1), 42-54 (2001).
31. 2. J. Neurosci. 23 (20), 7577-7585 (2003).
32. Goldin AL. Resurgence of sodium channel research. Annu. Rev. Physiol. 63, 871-894 (2001).
33. Trimmer JS, Rhodes KJ. Localization of voltage-gated ion channels in mammalian brain. Annu. Rev. Physiol. 66, 477-519 (2004).
34. + channel subtypes in central neurons. Neuron 3 (6), 695-704 (1989).
35. V1.1 loss-of-function mutations impair excitability of GABAergic neurons, consistently with reduced inhibition in cortical circuits.
36. v1.1 mutant mice: implications for ataxia in severe myoclonic epilepsy in infancy. J. Neurosci. 27 (41), 11065-11074 (2007).
37. Oakley JC, Kalume F, Yu FH, Scheuer T, Catterall WA. Temperature- and agedependent seizures in a mouse model of severe myoclonic epilepsy in infancy. Proc. Natl Acad. Sci. USA 106 (10), 3994-3999 (2009).
38. V) 1.1 localizes to axons of parvalbuminpositive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. J. Neurosci. 27 (22), 5903-5914 (2007).
39. Whitaker WR, Faull RL, Waldvogel HJ, Plumpton CJ, Emson PC, Clare JJ. Comparative distribution of voltage-gated sodium channel proteins in human brain. Brain Res. Mol. Brain Res. 88 (1-2), 37-53 (2001).
40. Hartmann HA, Colom LV, Sutherland ML, Noebels JL. Selective localization of cardiac SCN5A sodium channels in limbic regions of rat brain. Nat. Neurosci. 2 (7), 593-595 (1999).
41. Verkhratsky A, Steinhauser C. Ion channels in glial cells. Brain Res. Brain Res. Rev. 32 (2-3), 380-412 (2000).
42. Black JA, Liu S, Waxman SG. Sodium channel activity modulates multiple functions in microglia. Glia 57 (10), 1072-1081 (2009).
43. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nat. Rev. Neurosci. 5 (7), 553-564 (2004).
44. + channel a subunit in voltage-dependent gating and drug block. J. Biol. Chem. 277 (38), 35393-35401 (2002).
45. +) channel a subunit. J. Biol. Chem. 276 (1), 20-27 (2001).
46. Catterall WA, Cestele S, Yarov-Yarovoy V, Yu FH, Konoki K, Scheuer T. Voltagegated ion channels and gating modifier toxins. Toxicon 49 (2), 124-141 (2007).
47. Bartolomei F, Gastaldi M, Massacrier A, Planells R, Nicolas S, Cau P. Changes in the mRNAs encoding subtypes I, II and III sodium channel α subunits following kainate-induced seizures in rat brain. J. Neurocytol. 26 (10), 667-678 (1997).
48. Aronica E, Yankaya B, Troost D, van Vliet EA, Lopes da Silva FH, Gorter JA. Induction of neonatal sodium channel II and III α-isoform mRNAs in neurons and microglia after status epilepticus in the rat hippocampus. Eur. J. Neurosci. 13 (6), 1261-1266 (2001).
49. Klein JP, Khera DS, Nersesyan H, Kimchi EY, Waxman SG, Blumenfeld H. Dysregulation of sodium channel expression in cortical neurons in a rodent model of absence epilepsy. Brain Res. 1000 (1-2), 102-109 (2004).
50. Blumenfeld H, Lampert A, Klein JP et al. Role of hippocampal sodium channel Nav1.6 in kindling epileptogenesis. Epilepsia 50 (1), 44-55 (2009).
51. Lombardo AJ, Kuzniecky R, Powers RE, Brown GB. Altered brain sodium channel transcript levels in human epilepsy. Brain Res. Mol. Brain Res. 35 (1-2), 84-90 (1996).
52. Whitaker WR, Faull RL, Dragunow M, Mee EW, Emson PC, Clare JJ. Changes in the mRNAs encoding voltage-gated sodium channel types II and III in human epileptic hippocampus. Neuroscience 106 (2), 275-285 (2001).
53. Agrawal N, Alonso A, Ragsdale DS. Increased persistent sodium currents in rat entorhinal cortex layer V neurons in a post-status epilepticus model of temporal lobe epilepsy. Epilepsia 44 (12), 1601-1604 (2003).
54. Vreugdenhil M, Hoogland G, van Veelen CW, Wadman WJ. Persistent sodium current in subicular neurons isolated from patients with temporal lobe epilepsy. Eur. J. Neurosci. 19 (10), 2769-2778 (2004).
55. + current (INaP) can cause chronic seizures.
56. Meisler MH, Kearney JA. Sodium channel mutations in epilepsy and other neurological disorders. J. Clin. Invest. 115 (8), 2010-2017 (2005).
57. Mulley JC, Scheffer IE, Petrou S, Dibbens LM, Berkovic SF, Harkin LA. SCN1A mutations and epilepsy. Hum. Mutat. 25 (6), 535-542 (2005).
58. v1.1 mutations and genetic variants and presentation of a database for collecting them [102], a useful web resource similar to that of [59]. New variations can be submitted through the website to make the database as up to date as possible.
59. v1.1 variants [202], a useful web resource similar to that of [58]. New variations can be submitted through the website to make the database as up to date as possible.
60. Holland KD, Kearney JA, Glauser TA et al. Mutation of sodium channel SCN3A in a patient with cryptogenic pediatric partial epilepsy. Neurosci. Lett. 433 (1), 65-70 (2008).
61. Patino GA, Claes LR, Lopez-Santiago LF et al. A functional null mutation of SCN1B in a patient with Dravet syndrome. J. Neurosci. 29 (34), 10764-10778 (2009).
62. Singh NA, Pappas C, Dahle EJ et al. A role of SCN9A in human epilepsies, as a cause of febrile seizures and as a potential modifier of Dravet syndrome. PLoS Genet. 5 (9), e1000649 (2009).
63. Singh NA, Charlier C, Stauffer D et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat. Genet. 18 (1), 25-29 (1998).
64. Specchio N, Vigevano F. The spectrum of benign infantile seizures. Epilepsy Res. 70 (Suppl. 1), S156-S167 (2006).
65. Heron SE, Crossland KM, Andermann E et al. Sodium-channel defects in benign familial neonatal-infantile seizures. Lancet 360 (9336), 851-852 (2002).
66. Berkovic SF, Heron SE, Giordano L et al. Benign familial neonatal-infantile seizures: characterization of a new sodium channelopathy. Ann. Neurol. 55 (4), 550-557 (2004).
67. V) 1.2 in a patient with febrile and afebrile seizures causes channel dysfunction. Proc. Natl Acad. Sci. USA 98 (11), 6384-6389 (2001).
68. Ito M, Shirasaka Y, Hirose S, Sugawara T, Yamakawa K. Seizure phenotypes of a family with missense mutations in SCN2A. Pediatr. Neurol. 31 (2), 150-152 (2004).
69. Ogiwara I, Ito K, Sawaishi Y et al. De novo mutations of voltage-gated sodium channel αII gene SCN2A in intractable epilepsies. Neurology 73 (13), 1046-1053 (2009).
70. Shi X, Yasumoto S, Nakagawa E, Fukasawa T, Uchiya S, Hirose S. Missense mutation of the sodium channel gene SCN2A causes Dravet syndrome. Brain Dev. 31 (10), 758-762 (2009).
71. Scheffer IE, Berkovic SF. Generalized epilepsy with febrile seizures plus. A genetic disorder with heterogeneous clinical phenotypes. Brain 120 (Pt 3), 479-490 (1997). • The original description of generalized epilepsy with febrile seizures plus as a distinct clinical entity.
72. Singh R, Scheffer IE, Crossland K, Berkovic SF. Generalized epilepsy with febrile seizures plus: a common childhoodonset genetic epilepsy syndrome. Ann. Neurol. 45 (1), 75-81 (1999).
73. 1 subunit gene SCN1B. Nat. Genet. 19 (4), 366-370 (1998). • The first epileptogenic mutation indentified in a gene coding for a voltage-gated Na channel subunit.
74. + phenotypes associated with SCN1B mutations. Brain 130 (Pt 1), 100-109 (2007).
75. +2. Nat. Genet. 24 (4), 343-345 (2000). • Confirmation that voltage-gated Na channel mutations play a major role in some epilepsies; new concept of epilepsy as a Na channelopathy.
76. Baulac S, Gourfinkel-An I, Picard F et al. A second locus for familial generalized epilepsy with febrile seizures plus maps to chromosome 2q21-q33. Am. J. Hum. Genet. 65 (4), 1078-1085 (1999).
77. +), clinical spectrum in seven Italian families unrelated to SCN1A, SCN1B, and GABRG2 gene mutations. Epilepsia 45 (2), 149-158 (2004).
78. Dravet C, Bureau M, Oguni H, Fukuyama Y, Cokar O. Severe myoclonic epilepsy in infancy: Dravet syndrome. Adv. Neurol. 95, 71-102 (2005). • Book chapter with the accurate description of all the clinical, EEG and neuropsychological features of patient with Dravet syndrome (DS).
79. Oguni H, Hayashi K, Awaya Y, Fukuyama Y, Osawa M. Severe myoclonic epilepsy in infants - a review based on the Tokyo Women's Medical University series of 84 cases. Brain Dev. 23 (7), 736-748 (2001). • Confirmation that DS is a spectrum of phenotypes that includes patients without all the typical clinical features; those patients can be classified as borderline severe myoclonic epilepsy in infants or DS.
80. Wolff M, Casse-Perrot C, Dravet C. Severe myoclonic epilepsy of infants (Dravet syndrome), natural history and neuropsychological findings. Epilepsia 47 (Suppl. 2), 45-48 (2006).
81. Marini C, Mei D, Temudo T et al. Idiopathic epilepsies with seizures precipitated by fever and SCN1A abnormalities. Epilepsia 48 (9), 1678-1685 (2007).
82. Madia F, Striano P, Gennaro E et al. Cryptic chromosome deletions involving SCN1A in severe myoclonic epilepsy of infancy. Neurology 67 (7), 1230-1235 (2006).
83. Marini C, Scheffer IE, Nabbout R et al. SCN1A duplications and deletions detected in Dravet syndrome: implications for molecular diagnosis. Epilepsia 50 (7), 1670-1678 (2009). • Clinical and genetic study of a large cohort of DS patients: description of genotype-phenotype correlations and microchromosomal rearrangements including duplications and amplifications of SCN1A.
84. Wang J W, Kurahashi H, Ishii A et al. Microchromosomal deletions involving SCN1A and adjacent genes in severe myoclonic epilepsy in infancy. Epilepsia 49 (9), 1528-1534 (2008).
85. Fujiwara T, Watanabe M, Takahashi Y, Higashi T, Yagi K, Seino M. Long-term course of childhood epilepsy with intractable grand mal seizures. Jpn. J. Psychiatry Neurol. 46 (2), 297-302 (1992).
86. Fujiwara T, Sugawara T, Mazaki-Miyazaki E et al. Mutations of sodium channel α subunit type 1 (SCN1A) in intractable childhood epilepsies with frequent generalized tonic-clonic seizures. Brain 126 (Pt 3), 531-546 (2003).
87. Ebach K, Joos H, Doose H et al. SCN1A mutation analysis in myoclonic astatic epilepsy and severe idiopathic generalized epilepsy of infancy with generalized tonic-clonic seizures. Neuropediatrics 36 (3), 210-213 (2005).
88. Harkin LA, McMahon JM, Iona X et al. The spectrum of SCN1A-related infantile epileptic encephalopathies. Brain 130 (Pt 3), 843-852 (2007).
89. Grosso S, Orrico A, Galli L, Di Bartolo R, Sorrentino V, Balestri P. SCN1A mutation associated with atypical Panayiotopoulos syndrome. Neurology 69 (6), 609-611 (2007).
90. Livingston JH, Cross JH, Mclellan A, Birch R, Zuberi SM. A novel inherited mutation in the voltage sensor region of SCN1A is associated with Panayiotopoulos syndrome in siblings and generalized epilepsy with febrile seizures plus. J. Child Neurol. 24 (4), 503-508 (2009).
91. Baulac S, Gourfinkel-An I, Nabbout R et al. Fever, genes, and epilepsy. Lancet Neurol. 3 (7), 421-430 (2004).
92. Nakayama J. Progress in searching for the febrile seizure susceptibility genes. Brain Dev. 31 (5), 359-365 (2009).
93. v1.1 sodium channel (SCN1A) loss-of-function mutation associated with familial simple febrile seizures. Proc. Natl Acad. Sci. USA 102 (50), 18177-18182 (2005).
94. Colosimo E, Gambardella A, Mantegazza M et al. Electroclinical features of a family with simple febrile seizures and temporal lobe epilepsy associated with SCN1A loss-of-function mutation. Epilepsia 48 (9), 1691-1696 (2007).
95. Peiffer A, Thompson J, Charlier C et al. A locus for febrile seizures (FEB3) maps to chromosome 2q23-24. Ann. Neurol. 46 (4), 671-678 (1999).
96. Orrico A, Galli L, Grosso S et al. Mutational analysis of the SCN1A, SCN1B and GABRG2 genes in 150 Italian patients with idiopathic childhood epilepsies. Clin. Genet. 75 (6), 579-581 (2009).
97. Kanai K, Hirose S, Oguni H et al. Effect of localization of missense mutations in SCN1A on epilepsy phenotype severity. Neurology 63 (2), 329-334 (2004).
98. Kanai K, Yoshida S, Hirose S et al. Physicochemical property changes of amino acid residues that accompany missense mutations in SCN1A affect epilepsy phenotype severity. J. Med. Genet. 46 (10), 671-679 (2009).
99. Baroudi G, Carbonneau E, Pouliot V, Chahine M. SCN5A mutation (T1620M) causing Brugada syndrome exhibits different phenotypes when expressed in Xenopus oocytes and mammalian cells. FEBS Lett. 467 (1), 12-16 (2000).
100. v1.3 sodium channels: rapid repriming and slow closed-state inactivation display quantitative differences after expression in a mammalian cell line and in spinal sensory neurons. J. Neurosci. 21 (16), 5952-5961 (2001).
101. Chen YH, Dale TJ, Romanos MA, Whitaker WR, Xie XM, Clare JJ. Cloning, distribution and functional analysis of the type III sodium channel from human brain. Eur. J. Neurosci. 12 (12), 4281-4289 (2000).
102. Alekov A, Rahman MM, Mitrovic N, Lehmann-Horn F, Lerche H. A sodium channel mutation causing epilepsy in man exhibits subtle defects in fast inactivation and activation in vitro. J. Physiol. 529 (Pt 3), 533-539 (2000).
103. Spampanato J, Escayg A, Meisler MH, Goldin AL. Functional effects of two voltage-gated sodium channel mutations that cause generalized epilepsy with febrile seizures plus type 2. J. Neurosci. 21 (19), 7481-7490 (2001).
104. Rhodes TH, Lossin C, Vanoye CG, Wang DW, George AL Jr. Noninactivating voltage-gated sodium channels in severe myoclonic epilepsy of infancy. Proc. Natl Acad. Sci. USA 101 (30), 11147-11152 (2004).
105. Isom LL, De Jongh KS, Catterall WA. Auxiliary subunits of voltage-gated ion channels. Neuron 12 (6), 1183-1194 (1994).
106. 3 subunits. Mol. Cell Neurosci. 18 (5), 570-580 (2001).
107. 1 subunit mutation responsible for generalized epilepsy with febrile seizures plus type 1. J. Neurosci. 22 (24), 10699-10709 (2002).
108. 1-subunit mutation. Biochem. Biophys. Res. Commun. 291 (4), 1095-1101 (2002).
109. Wallace RH, Scheffer IE, Parasivam G et al. Generalized epilepsy with febrile seizures plus: mutation of the sodium channel subunit SCN1B. Neurology 58 (9), 1426-1429 (2002).
110. 1 subunit mutations severely reduce β subunitmediated modulation of sodium channel function. Neuroscience 148 (1), 164-174 (2007).
111. 5 dopamine receptor activation differentially modulates rapidly inactivating and persistent sodium currents in prefrontal cortex pyramidal neurons. J. Neurosci. 21 (7), 2268-2277 (2001).
112. +) mutation. Neurobiol. Dis. 35 (1), 91-102 (2009). • Demonstration that missense voltage-gated sodium channel mutants can have neuron subtype-specific properties, which may be different from those observed in cell lines.
113. Martin MS, Dutt K, Papale LA et al. Altered function of the SCN1A voltagegated sodium channel leads to GABAergic interneuron abnormalities. J. Biol. Chem. DOI: 10.1074/jbc. M109.078568 (2010) (Epub ahead of print).
114. v1.1 sodium channels cause epilepsy? Brain Res. Rev. 58 (1), 149-159 (2008).
115. + channel mutant. J. Neurosci. 27 (41), 11037-11046 (2007). • Identification of the first epileptogenic folding defective voltage-gated Na channel mutant that can be rescued by molecular interactions.
116. v1.1 related epilepsies? Hum. Mutat. 30 (7), E747-E760 (2009).
117. Stafstrom CE. Traffic jam at the sodium channel. Epilepsy Curr. 8 (3), 81-82 (2008).
118. + channel causing benign familial neonatal-infantile seizures. J. Neurosci. 26 (40), 10100-10109 (2006).
119. Xu R, Thomas EA, Jenkins M et al. A childhood epilepsy mutation reveals a role for developmentally regulated splicing of a sodium channel. Mol. Cell. Neurosci. 35 (2), 292-301 (2007).
120. v) 1.6 at developing CNS nodes of Ranvier. Neuron 30 (1), 105-119 (2001).
121. Boiko T, Rasband MN, Levinson SR et al. Compact myelin dictates the differential targeting of two sodium channel isoforms in the same axon. Neuron 30 (1), 91-104 (2001).
122. V1.2 function and reduced cell surface expression in benign familial neonatal-infantile seizures. Epilepsia 49 (9), 1535-1545 (2008).
123. Dichgans M, Freilinger T, Eckstein G et al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet 366 (9483), 371-377 (2005).
124. Gargus JJ, Tournay A. Novel mutation confirms seizure locus SCN1A is also familial hemiplegic migraine locus FHM3. Pediatr. Neurol. 37 (6), 407-410 (2007).
125. + channel. J. Neurosci. 28 (29), 7273-7283 (2008).
126. Kahlig KM, Rhodes TH, Pusch M et al. Divergent sodium channel defects in familial hemiplegic migraine. Proc. Natl Acad. Sci. USA 105 (28), 9799-9804 (2008).
127. Pietrobon D. Familial hemiplegic migraine. Neurotherapeutics 4 (2), 274-284 (2007).
128. Avoli M, Nagao T, Kohling R, Lucke A, Mattia D. Synchronization of rat hippocampal neurons in the absence of excitatory amino acid-mediated transmission. Brain Res. 735 (2), 188-196 (1996).
129. Vahedi K, Depienne C, Le Fort D et al. Elicited repetitive daily blindness: a new phenotype associated with hemiplegic migraine and SCN1A mutations. Neurology 72 (13), 1178-1183 (2009).
130. Osaka H, Ogiwara I, Mazaki E et al. Patients with a sodium channel α 1 gene mutation show wide phenotypic variation. Epilepsy Res. 75 (1), 46-51 (2007).
131. Weiss LA, Escayg A, Kearney JA et al. Sodium channels SCN1A, SCN2A and SCN3A in familial autism. Mol. Psychiatry 8 (2), 186-194 (2003).
132. Riva D, Vago C, Pantaleoni C, Bulgheroni S, Mantegazza M, Franceschetti S. Progressive neurocognitive decline in two children with Dravet syndrome, de novo SCN1A truncations and different epileptic phenotypes. Am. J. Med. Genet. A 149 A (10), 2339-2345 (2009).
133. Trudeau MM, Dalton JC, Day JW, Ranum LP, Meisler MH. Heterozygosity for a protein truncation mutation of sodium channel SCN8A in a patient with cerebellar atrophy, ataxia, and mental retardation. J. Med. Genet. 43 (6), 527-530 (2006).
134. 2-subunit regulates cell adhesion and migration. J. Biol. Chem. 280 (24), 23251-23261 (2005).
135. Wong HK, Sakurai T, Oyama F et al. β subunits of voltage-gated sodium channels are novel substrates of β-site amyloid precursor protein-cleaving enzyme (BACE1) and γ-secretase. J. Biol. Chem. 280 (24), 23009-23017 (2005).
136. v1.1, thus with a mechanism similar to that of epileptogenic mutations.
137. Smith KJ. Sodium channels and multiple sclerosis: roles in symptom production, damage and therapy. Brain Pathol. 17 (2), 230-242 (2007).
138. Delgado-Escueta AV, Bourgeois BF. Debate: does genetic information in humans help us treat patients? Pro - genetic information in humans helps us treat patients. Con - genetic information does not help at all. Epilepsia 49 (Suppl. 9), 13-24 (2008).
139. Ottman R, Hirose S, Jain S et al. Genetic testing in the epilepsies - report of the ILAE Genetics Commission. Epilepsia 51 (4), 655-670 (2010).
140. Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 39 (5), 508-512 (1998).
141. Chiron C, Marchand MC, Tran A et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 356 (9242), 1638-1642 (2000).
142. Fisher JL. The anti-convulsant stiripentol acts directly on the GABA (A) receptor as a positive allosteric modulator. Neuropharmacology 56 (1), 190-197 (2009).
143. Martin MS, Tang B, Papale LA, Yu FH, Catterall WA, Escayg A. The voltage-gated sodium channel Scn8a is a genetic modifier of severe myoclonic epilepsy of infancy. Hum. Mol. Genet. 16 (23), 2892-2899 (2007).
144. Sakmann B, Neher E. Single-Channel Recording (Second Edition). Plenum Press, London, UK (1995).
145. Hille B. Ionic Channels of Excitable Membranes. Sinauer Associates Inc., MA, USA (2001).